When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a yet-to-be-determined name and is expected to trade on the New ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint.

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion.

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Endo Inc. said Tuesday it has entered into an agreement to divest its international pharmaceuticals business to Knight Therapeutics in a deal valued at up to $99 million. The proposed sale ...

Malvern-based Endo has found a merger partner, agreeing to combine with another troubled pharmaceutical firm in a deal valued ...

Endo, Inc. (OTCQX: NDOI) announced today the launch of a first-of-its-kind initiative for a pharmaceutical company: the ...

Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated through Canada ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...